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ABSTRACT 
Purpose of the Review: Bisphosphonates have well-established effects on suppressing bone 
resorption and slowing bone loss yet the effects on bone mechanical properties are less clear.  
We review recent data from pre-clinical and clinical experiments that assessed mechanical 
properties of bisphosphonate-treated specimens.   
 
Recent Findings: Pre-clinical work has utilized new techniques to show reduced fatigue life and 
transfer of stress from the mineral-to-collagen. Several notable studies having examined 
mechanical properties of tissue from patients treated with bisphosphonates with mixed results. 
Pre-clinical data suggest effects on mechanics may be independent of remodeling suppression. 
 
Summary: The direct effect of bisphosphonates on bone mechanics remains unclear but recent 
work has set a solid foundation for the coming years. 
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Today’s clinicians have plenty of options for reducing the risk of fracture in their patients.  
Bisphosphonates, selective estrogen receptor modulators (SERM), parathyroid hormone, 
hormone replacement therapy, Rank-L inhibitors, and parathyroid hormone related protein 
analogs are all FDA-approved and generally effective.  Each drug (or drug class) works through 
a slightly different mechanism but in general affect bone cell activity to either make more bone or 
slow the loss. Moving from altered bone mass to altered mechanics is more challenging. A 
population-based positive correlation between bone mass and fracture risk has led to the 
assumption that changes in bone mass reflect changes in actual mechanical properties. Yet as 
the London playwright Oscar Wilde wrote, “The truth is rarely pure and never simple”.    
 
The bisphosphonate pamidronate was FDA approved in 1991 for treatment of malignancy-
induced hypercalcemia, Paget’s disease, and osteolytic bone lesions. Four years later 
alendronate received FDA approval for treatment/prevention of osteoporosis. Prior to 1995, less 
than 20 papers described the effects of bisphosphonates on bone mechanical properties, only 
two of which used alendronate (others focused on pamidronate, etidronate, and tiludronate).   
Thus, the vast majority of work describing ‘bisphosphonates and mechanical properties’ (>250 
PubMed citations) has been performed in the 20+ years following their entry into the osteoporosis 
clinic (Figure 1). Even now as data continues to emerge the answer to the question ‘How does 
bisphosphonate treatment affect mechanical properties’ does not appear simple.  The goal of this 
brief review is to highlight work related to this question of the past few years (2014-now). 
  
Three atypical fractures re-ignited the flame of interest around bisphosphonates and bone 
mechanics 
In 2005, Odvina and colleagues described a series of patients that had ‘severely suppressed bone 
turnover’ associated with bisphosphonate treatment [1]. A sub-set of these patients (n=3) 
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experienced what the authors called ‘atypical fractures’ of the femur shaft.  In the years to follow 
there emerged a growing number of reports described similar atypical femoral fractures that were 
associated with bisphosphonate treatment.  Collectively, these report spurred several consensus 
statements, most of which highlighted that there was a gap in our understanding of how 
bisphosphonates affect bone mechanical properties – most notably after prolonged treatment [2-
6]. The number of papers related to bisphosphonates and mechanical properties nearly doubled 
in the years following the work of Odvina compared to a similar period prior (Figure 1). This has 
moved the field forward by spurring novel approaches to studying the question in preclinical work 
and, most importantly, pushing for mechanical data in clinical samples. 
 
Pre-clinical mechanical data – Finally moving beyond monotonic tests  
The majority of work underpinning the skeletal mechanisms of bisphosphonates was carried out 
in rodent models. Because of this, the fundamental effects these drugs impart on bone 
mechanical properties came from rodents. Mechanical data in rodents, while informative, has 
limitations [7]. Most notably, the absence of intracortical remodeling in normal rodents does not 
provide a realistic model reflecting how remodeling suppression in cortical bone occurs in 
humans. Assuming that the effects bisphosphonates have on mechanical properties are driven 
by remodeling suppression (see final section of this review), this limitation is significant.  
 Large animal models (those with intracortical remodeling such as dog, sheep, non-human 
primates) provide a cloudy picture of bisphosphonate-induced effects on mechanical properties 
[8]. Results differ depending on species, skeletal site, duration of treatment, mechanical 
parameter being assessed, mode of testing, and on and on and on. Etidronate, an early 
generation bisphosphonate, resulted in negative effects on bone structural-level mechanical 
properties in large animal models [9]. Subsequently-developed bisphosphonates, including those 
approved for reducing fracture risk, have mostly documented increased structural mechanical 
properties in large animal models based on whole bone tests (see summary of papers here [10]). 
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Material properties, estimated through back-calculation of structure tests or through testing 
machined specimens, have shown positive, neutral, and negative effects from bisphosphonate 
treatment in various studies [10].  
 Two recent papers have investigated the mechanical effects of bisphosphonates using 
novel testing techniques on canine bone. The first advances our understanding of mechanical 
properties beyond monotonic properties, the mode of testing in the majority of previous 
experiments.  In this work, cyclic loading tests were performed on bone beams machined from 
the cortical bone of dog ribs [11]. This skeletal site has high bone turnover (~20%/year) which has 
been shown to be significantly suppressed following 3-years of alendronate treatment at clinically 
relevant doses [12]. Fatigue life in these cortical bone beams was 3-fold lower in animals that had 
been treated with high doses of alendronate compared to control. There was no significant effect 
at the lower dose (representing an estimation of the dose used clinically on a mg/kg basis). The 
reduction in the high dose animals was associated with a number of differences in structure, such 
as the size of osteons and lacunar density, suggesting that changes manifesting from the 
suppression of remodeling might play a role in the compromised fatigue life. The major advance 
of this work is that it attempts to model failure of bone in a more life-like situation. While it can be 
argued that fatigue studies are not realistic, they certainly test how bone fails when exposed to 
sub-damaging loads over time, most notably in conditions where remodeling activity is 
significantly suppressed. Outside of impact testing (which would be really valuable to assess in 
bisphosphonate-treated tissue), fatigue tests produce some of the most useful data with respect 
to how drugs affect functional bone properties.  
 The second recent study that provides novel data assessed cortical bone beams from 
canine humeri (3 years of treatment with alendronate at a clinically relevant dose) [13]. The 
authors performed a wide range of mechanical tests on the cortical beams including monotonic 
bending, fracture toughness testing (using notched specimens) and small-angle x-ray 
scattering/wide-angle x-ray diffraction (SAXS/WAXS) during tensile testing. The monotonic and 
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tensile tests showed lower post-yield properties in alendronate-treated animals, although only 
some parameters reached statistical significance. Fracture toughness tests revealed no 
difference between control and bisphosphonate-treated groups for crack initiation or crack growth 
toughness among groups. SAXS/WAXS tests, in tension, showed the two groups had identical 
responses of tissue stress/strain at small strains while at higher strains there was a significant 
degradation in post-yield deformation in bone from alendronate-treated animals (Figure 2). 
Partitioning this out into how the two components of bone handle the strain, the authors concluded 
that the strain carried by the collagen, but not the mineral, was compromised in treated animals. 
This was hypothesized to be related to the increase in non-enzymatic collagen cross-linking, 
associated with bisphosphonate treatment which would limit the ability of the collagen fibers to 
slide and dissipate energy prior to breaking.  Increased non-enzymatic collagen cross-linking was 
noted in the samples tested in this work, similar to what has been documented in other pre-clinical 
bisphosphonate studies [14-16]. Certainly, it remains plausible that other alterations in collagen 
or the collagen/mineral interface, besides cross-linking, are responsible for these effects. The 
major advance of this work is that it attempts to dive a bit deeper into the mechanical effects, 
partitioning out collagen and mineral.  These sorts of studies have the potential to truly determine 
the mechanical mechanisms at play with bisphosphonate treatment. 
  
Mechanical data from bisphosphonate-treated patients – More anticipated than a Star Wars 
movie 
The most exciting work emerging in the field over the past few years comes from the handful of 
studies describing effects of bisphosphonates on mechanical properties using human tissue. 
Obtaining and working with human tissue is challenging. Sample sizes tend to be low, control 
tissue often involves use of cadaver material, and duration of bisphosphonate use is often 
variable.  Despite these limitations (and others) such data provide the closest look we have to 
what is happening in the patients we are ultimately trying to benefit with treatment.  
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 A series of two papers, by the same laboratory, have described properties of femoral head 
trabecular bone tissue from patients that experienced a femoral neck fracture and were 
undergoing surgery [17,18]. Groups included those that had taken bisphosphonates and those 
that had not, along with cadaveric non-fracture controls. Treated patients had taken weekly oral 
alendronate for 1-9 years (average 3), based on patient records. Cylindrical cores (~10 x 7 mm) 
were taken from the region directly superior to the trabecular chiasma in the primary compressive 
trabecular arcade of the femoral heads. Samples were assessed using synchrotron imaging (to 
examine microdamage) and compression mechanical testing. Bone samples from 
bisphosphonate-treated individuals had significantly lower strength and modulus, both at the 
whole core level and at the tissue level (correcting for the amount of bone volume) compared to 
both the fracture and non-fracture controls. Bisphosphonate-treated patients had higher 
microcrack density and volume compared to both non-bisphosphonate fracture and non-fracture 
control groups. The authors concluded that the femoral head bone of bisphosphonate-treated 
patients was weaker and this could be due to the associated higher amount of microdamage in 
the tissue, presumably from reduced remodeling. The most notable weakness of this paper is that 
the tissues were from those patients that fractured.  Given that the bisphosphonate group didn’t 
have higher trabecular bone volume compared to controls (at least in one of the reports [17]), 
combined with the fact that they fractured, raises the question of whether these results are 
generalizable to the larger population of treated patients or if these represent non-responders to 
the treatment. 
 In a similar study design, albeit using mid-femoral diaphysis tissue from cadavers, 
properties were examined from three distinct cohorts: young healthy individuals (no disease, 
mean age of 35), individuals with osteoporosis based on medical records but without a history of 
bisphosphonates, and individuals with osteoporosis and a medical record of taking 
bisphosphonates (alendronate) for 6 years [19]. The mean age of the latter two groups was 80.  
A number of analyses were conducted including high resolution CT, 3-pt bending, SAXS and 
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fractography. Unlike the above studies, this work focused on cortical bone, taken from the lateral 
cortex of the femur and machined into beam specimens. Various morphological differences 
existed between the specimens from young individuals and those from the two aged cohorts (such 
as porosity), but there were no mechanical property differences between those with osteoporosis 
and those with osteoporosis treated with bisphosphonates either at low or high strain (Figure 3). 
This includes no difference in fibril strain, which was the property shown above (in canine studies) 
to be most affected by bisphosphonates.    
 Single trabeculae from the L5 of cadavers were assessed for mechanical properties in 
three groups: control (osteoporosis but no treatment), short term bisphosphonate treatment (1-5 
years) and long-term bisphosphonate treatment (6+ years) [20]. Details of bisphosphonate 
treatment were obtained from the family and medical records and consisted of weekly alendronate 
in all cases. Microdamage, assessed histologically, was non-significantly lower in the two treated 
groups compared to controls.  Young’s modulus, ultimate stress, work to failure and toughness of 
single trabeculae, tested in bending, did not different among the three groups. Based on these 
data the authors concluded that alendronate treatment, even beyond 6 years, has no adverse 
impact on vertebral trabecular bone mechanical properties. Two main considerations in this work 
are the efficacy of the treatment and the tissue assessment.  Trabecular BV/TV was lower in those 
on bisphosphonate compared to control, questioning the effectiveness of treatment, although 
erosion surface was significantly lower and tissue mineral density was significantly higher 
compared to controls.  The latter effects would be consistent with drug efficacy.  The second 
consideration is the method of mechanical testing.  Although there is great value in determining 
the mechanics of single trabeculae, the isolation of a single trabeculae may not reflect the 
properties of the larger network.  
 The most direct work aimed at understanding bone mechanical properties in the context 
of atypical femoral fracture bone mechanics utilizes tissue from individuals who have experienced 
these fractures [21]. Cortical bone tissue from the lateral aspect of the proximal femur was 
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collected from individuals treated with bisphosphonates that had experienced an atypical fracture, 
those treated with bisphosphonates that experienced a typical fracture (intertrochanteric), those 
treated with bisphosphonates without a fracture (undergoing total hip arthroplasty as treatment 
for osteoarthritis), those without a history of bisphosphonate treatment that experienced a typical 
fracture (intertrochanteric), or those without a history of bisphosphonate treatment who had not 
fractured.  Obtaining such a collection of tissues is amazing, as is the fact that the authors could 
perform mechanical tests on such tissue. Bisphosphonate-treated patients had been using 
alendronate, ibandronate, or risedronate for an average duration of ~ 7 years. All tissue was 
embedded in plastic and then subjected to various assessments, including fracture toughness 
and nanoindentation. Mechanics on embedded tissue has notable limitations which should not be 
ignored (plastic carries some load, the in-situ collagen/mineral organization may be disrupted, 
tissue is dehydrated prior to embedding affecting water, etc), yet given that all tissues were treated 
the same, there remains utility in the relative effects across treatments.  That said, it cannot be 
discounted that embedding has differential effects across treatment groups which could affect 
results and interpretation of this work. Based on nanoindentation, cortical bone from patients with 
atypical fractures had hardness values similar to that of other bisphosphonate-treated patients. 
Hardness of patients treated with bisphosphonates was collectively higher than non-fracture non-
bisphosphonate patient tissue but not non-bisphosphonate fracture patients. Fracture toughness 
tests on notched specimens revealed that cortical bone from patients on bisphosphonates had 
reduced fracture resistance compared to treatment naïve patients; no difference existed between 
those with and without fracture within the bisphosphonate cohort. The authors also described 
different patterns of crack growth, with cracks in bisphosphonate-treated bone being less tortuous 
and following a more distinct crack path. Similar to the works above, there are few pieces of data 
in the work that document ‘efficacy’ of bisphosphonates, that is properties of mineralization are 
mostly unchanged compared to non-treated individuals. It’s possible that the lack of effects on 
parameters such as bone volume, or mineral/matrix ratio (mean and/or distribution heterogeneity) 
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are not showing bisphosphonate effects due to low sample size, yet the commonality of this 
finding among all these human studies makes one stop and ponder – are the effects observed in 
animals reflective of what is happening in humans?  Additional work on human tissue will be 
needed to reveal the answer. 
 A fundamentally different type of human tissue assessment, using finite element analyses, 
asked the question of how estimated bone mechanical properties might look like with long term 
bisphosphonate treatment [22]. Iliac crest bone biopsies were obtained from treatment naïve 
patients or patients treated with oral bisphosphonate (alendronate, risedronate, ibandronate) for 
up to 16 years (range 1-16 years).  Biopsies were imaged with high resolution computed 
tomography and the central portion of the scan (mid-4mm trabecular section) was computationally 
meshed, assigned homogeneous material properties, and subjected to computational loading. 
The assumption of homogenous material properties’, which is commonly used in similar models, 
has limitations in the context of bisphosphonates as these would be expected to be altered 
(although its unknown exactly how – the point of this review). The computational models showed 
that mechanical properties such as apparent stiffness and failure stress had second-order 
polynomial relationship, with increasing properties up to about 7 years and decreasing properties 
thereafter. These results are most conservatively interpreted as suggesting that despite 
bisphosphonate-treatment there are changes in the structure over time that result in a loss of the 
benefits conferred during early treatment.  
 
in vivo assessment of bisphosphonate-induced tissue properties 
The section above highlights studies based on biopsy or other tissue sample that were removed 
from the patient during surgery (or post-mortem). A limitation of this work is that the study design 
is cross-sectional and thus the variability can be large. Over the past several years, indentation-
based techniques have emerged that have the potential to measure tissue properties in vivo [23]. 
These techniques have recently been used to explore the effects of long-term bisphosphonate 
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treatment [24]. Patients that had taken bisphosphonates for more than four years were separated 
into two groups, those that fractured on treatment and those that did not. The majority of fractures 
were vertebral fractures. In vivo impact microindentation was performed on the mid-tibia cortical 
bone and the lone parameter, bone material strength index (BMSi) was calculated. Individuals 
who had taken bisphosphonates and fractured had significantly lower BMSi compared to treated 
patients that had not fractured. This is consistent with previous data in which the indentation 
properties of long-term bisphosphonate-treated patients were assessed using a different type of 
impact microindentation [25]. In that work the indentation properties of those treated with 
bisphosphonates were not different from controls, and it was the presence of fracture that dictated 
whether indentation properties were different or not [25].  While these data suggest that in vivo 
indentation measures may be able to detect differential properties in fractured versus non-
fractured bone there is no evidence to date that bisphosphonate treatment is detectible in humans 
using this method.  
   
Bisphosphonates and mechanics – Where do we go from here? 
The generation of human data in the realm of bisphosphonates and mechanics represents a 
significant step forward for the field.  While it hasn’t provided a definitive answer to if/how these 
agents affect mechanics, it has laid a solid foundation on which we can build future questions and 
experiments. The next step will be to continue exploring mechanics, using a variety of techniques 
and tissues while at the same time looking deeper into other tissue properties to begin to answer 
the question of why bisphosphonates may be affecting mechanics (either universally or in select 
situations). Some studies have looked at properties of remodeling alterations, some at physical 
differences (lacunar density and microdamage) and others at properties of mineral or collagen. 
The incorporation of these tissue assessments is essential in an attempt to find some common 
ground of effects and the more of these properties that can be measured in each study the better. 
Obviously, the most efficient way to achieve such a goal is to foster collaborations across groups.  
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 The basic premise of this whole concept is that bisphosphonates suppress remodeling 
and that, with longer term exposure, there are consequences of reduced remodeling that leave 
the tissue more potentially brittle. A recent experiment by our laboratory explored the effects of 
bisphosphonate treatment on two different commonly used mouse strains (A/J and B6) [26]. While 
we found that the response of mechanical properties was highly divergent (B6 animals had 
significant lower post-yield properties while A/J were unchanged) an equally interesting outcome 
is the fact that mice have reduced mechanics at all.  As noted at the start of this review, mice 
don’t experience intracortical remodeling, certainly not at the age used in this work.  So how 
exactly could bisphosphonates alter mechanical properties in such an experiment (and numerous 
other rodent papers in the literature)?  
 It is well accepted that bisphosphonates bind to the skeleton (it’s how they impart their 
anti-remodeling effect) and that this retention is dose dependent [27]. They bind to exposed bone 
surfaces and also penetrate deep into the matrix through the canalicular system [28]. Based on 
this we asked the question of whether incorporation of bisphosphonate in the bone matrix could 
affect mechanical properties. In a series of unpublished experiments, one where we dosed 
animals with bisphosphonate and then examined acute effects on mechanics (within 48 hrs of 
dosing) and another where we exposed bones to bisphosphonate in situ, we found significantly 
lower mechanical properties, specifically those in the post-yield region (Figure 5). Furthermore, 
we have quantified bisphosphonate accumulation differences in the cortex of A/J and B6 mice 
which follow patterns consistent with strain-specific effects on bone mechanics noted above [26]. 
Although more work is necessary, these results set up the provocative hypothesis that physical 
effects of the bisphosphonate accumulation in the matrix could play a role in altering mechanical 
properties.  
 “The truth is rarely pure and never simple”. This certainly seems to concisely frame the 
question of how bisphosphonates affect bone mechanical properties. Yet it's a question that still 
deserves investigation given that these drugs are highly effective at reducing fracture risk. 
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Hopefully there continues to be investment in answering the question and the slope of publications 
shown in Figure 1 continues on a steep upward trajectory.   
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Figure Legends 
 
Figure 1. PubMed results for a search on ‘bisphosphonates AND mechanical properties’ show a 
steady rise in publications since the late 1980’s.  A near doubling of publications occurred around 
2005, coinciding with the publication of the first paper describing atypical femoral fractures [1]. 
Note, the final bar denotes only 3 years while all other bars are 5 year increments. 
 
Figure 2. Pre-clinical data showing the effects of bisphosphonates on mechanical properties, 
partitioned out into effects on the mineral and collagen using small-angle x-ray scattering/wide-
angle x-ray diffraction (SAXS/WAXS).  Cortical bone beams from canine treated with alendronate 
(BP-treated) or vehicle (control) were assessed using uniaxial tensile testing. (A) Stress/Strain 
curves showing the strains measured in the bone tissue and compared with strains measured in 
(B) the mineralized collagen fibril (stagger in the gap zone) using SAXS and (C) the HA mineral 
crystalline lattice using WAXD experiments. Reproduced with permission from Bone. [13]. 
Figure 3.  Clinical specimen data showing the effects of bisphosphonates on mechanical 
properties, partitioned out into effects on the mineral and collagen using small-angle x-ray 
scattering/wide-angle x-ray diffraction (SAXS/WAXS). Human cortical bone samples from the 
mid- diaphysis of the femur were used for assessment. (A) Stress-strain curves are shown for 
young, osteoporosis (OP) and bisphosphonate-treated (BP) cases. The shaded area contains all 
of the stress-strain curves for each group. (B) Fibril strain at low strain rate (B) and high strain 
rate (C), was assessed using synchrotron SAXS to determine the elastic stretching of the fibrils 
during the initial linear portion of the curve. At low strain rates (B) osteoporosis cases have a more 
pronounced plateau in the fibril strain (p < 0.001), indicating lower fibril deformation than the young 
cases. In contrast, the bisphosphonate-treated cases exhibit more fibrillar deformation, which 
corresponds to the behavior of the young cases, and may explain the improvements in strength. 
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At the high strain rates (C) the fibril versus tissue strain is very linear for all three conditions. 
Reproduced from [19] under the creative commons license.    
Figure 4.  Fracture resistance R-curves of stress intensity (K) as a function of crack extension, 
Δa, based on in situ fracture toughness tests. Lines represent a fit of the data for each group. 
Tissue from patients treated with bisphosphonates (+BIS groups) was less tough than that from 
bisphosphonate-naïve patients (−BIS groups); *P = 0.01. In addition, tissue from patients without 
fractures (−BIS Nonfx) was tougher than that from patients with typical or atypical fractures (P = 
0.03 by linear fixed effects model). Reproduced with permission (Proceedings of the National 
Academy of Sciences of the United States of America). [21] 
Figure 5.  Acute effect of zoledronate on mechanical properties. (A) Zoledronate was 
administered to 16-week-old male C57/B6 male mice on two consecutive days after which femora 
were extracted and tested in 4-point bending. Work to failure was significantly lower in animals 
treated with 48 hours of zoledronate compared to control (n=10/gp). (B) Femoral bones from 16-
week-old male C57/B6 male mice were soaked in situ in control (phosphate buffered saline) or 
zoledronic acid (100 µm concentration) in a 37-degree incubator for 48 hours (n=12 
bones/condition). Bones were then subjected to mechanical testing. Work to failure was 
significantly lower in bones soaked in zoledronate compared to control (n=10/gp). Together, these 
data suggest bisphosphonates, through binding within the bone matrix, could be having a physical 
effect on bone mechanics. Both experiments were approved by the Indiana University Institutional 
Animal Care and Use Committee prior to activity. 
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